Emerging treatments for Crohn’s disease and ulcerative colitis are expected to be more effective and safer than the existing treatments, such as Humira, Remicade, and Entyvio, that are widely available today.
Below are some of the emerging treatments available through clinical trials researchers and patients are excited about. By following the link, you can see if you qualify for the study and can then consider the treatment as one of your current options for treating your Crohn’s disease or ulcerative colitis.
Adalimumab vs Ustekinumab for Crohn’s
Etrolizumab for Crohn’s and ulcerative colitis
Guselkumab for Crohn’s
Guselkumab for ulcerative colitis
JNJ-64304500 for Crohn’s
Mirikizumab for ulcerative colitis
QBECO SSI for Crohn’s]
It takes years before emerging treatments like these are widely available. The only way to get early access to new IBD medications is through a clinical trial. While clinical trials provide patients with valuable access to new IBD medications, but not all trials are available to everyone. Learn the important considerations for the timing and types of IBD treatment that you take in order to keep your options for clinical trials open.
We hope this is helpful to you as you try to put your inflammatory bowel disease (IBD) into remission and regain your quality of life.